Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Gyre Therapeutics (GYRE) over the last 14 years, with Q3 2025 value amounting to $15.8 million.

  • Gyre Therapeutics' Non-cash Items fell 1166.88% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year decrease of 1166.88%. This contributed to the annual value of $190.4 million for FY2024, which is 94243.7% up from last year.
  • Latest data reveals that Gyre Therapeutics reported Non-cash Items of $15.8 million as of Q3 2025, which was down 1166.88% from $15.6 million recorded in Q2 2025.
  • Gyre Therapeutics' Non-cash Items' 5-year high stood at $444.2 million during Q4 2023, with a 5-year trough of $1.2 million in Q1 2021.
  • Moreover, its 5-year median value for Non-cash Items was $7.6 million (2023), whereas its average is $41.3 million.
  • In the last 5 years, Gyre Therapeutics' Non-cash Items surged by 340672.61% in 2023 and then tumbled by 5714.13% in 2024.
  • Over the past 5 years, Gyre Therapeutics' Non-cash Items (Quarter) stood at $1.5 million in 2021, then skyrocketed by 737.19% to $12.7 million in 2022, then skyrocketed by 3406.73% to $444.2 million in 2023, then tumbled by 57.14% to $190.4 million in 2024, then tumbled by 91.71% to $15.8 million in 2025.
  • Its Non-cash Items was $15.8 million in Q3 2025, compared to $15.6 million in Q2 2025 and $16.2 million in Q1 2025.